Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.
Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratio...
Main Authors: | Shuling Chen, Lixia Huang, Kaiyu Sun, Dexi Wu, Minrui Li, Manying Li, Bihui Zhong, Minhu Chen, Shenghong Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4431777?pdf=render |
Similar Items
-
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
by: Pfitzenmaier Jesco, et al.
Published: (2010-10-01) -
Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma
by: Jing Zeng, et al.
Published: (2022-11-01) -
Enhancer of zeste homolog 2 regulates cell differentiation and proliferation in neuroblastoma
by: Amallia N. Setyawati, et al.
Published: (2014-12-01) -
Impact of Enhancer of Zeste Homolog 2 on T Helper Cell-Mediated Allergic Rhinitis
by: Tsung-Yun Hou, et al.
Published: (2017-07-01) -
Enhancer of zeste homolog 2 induces pulmonary artery smooth muscle cell proliferation.
by: Salman A Aljubran, et al.
Published: (2012-01-01)